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Pre-therapeutic dosimetry with
radiolabelled somatostatin analogues in
patients with advanced neuroendocrine
tumours
Dear Sir,
Helisch and co-workers have reported important data on
pre-therapeutic dosimetry with radiolabelled somatostatin
analogues in patients with advanced neuroendocrine tu-
mours (Eur J Nucl MedMol Imaging 2004;31:1386–1392).
They compared the dosimetry and biodistribution of [86Y-
DOTA-D-Phe1-Tyr3]-octreotide (DOTA-TOC) with those
of 111In-pentetreotide. They concluded that adequate
dosimetry prior to 90Y-DOTA-TOC therapy is mandatory
and that dosimetry with both compounds is possible, al-
though dosimetry with 86Y-DOTA-TOC is more adequate.
The latter finding is not surprising since 86Y is the almost
perfect surrogate for 90Y and since dosimetry with 86Y-
DOTA-TOC was defined as the gold standard by the
authors.
The authors point out that dosimetry with 86Y-DOTA-
TOC is not widely available owing to the limited access to
the radionuclide and the elaborate correction algorithm
required. Therefore in our opinion the aim should be to find
a more widely feasible method for pre-therapeutic or, as
we suggest, peri-therapeutic dosimetry. Since the aim is an
effective treatment with 90Y-DOTA-TOC, we think that do-
simetry on planar scintigraphic images should be per-
formed with DOTA-TOC. It is known that the two peptides
pentetreotide and DOTA-TOC have different affinity pro-
files on somatostatin receptors [1, 2]. If pre-therapeutic
dosimetry is demanded by an ethical committee or by
authorities, we suggest the use of 111In-DOTA-TOC if 86Y-
DOTA-D-Phe1-Tyr3-octreotide is not available.
The treatment protocol presented by the authors foresees
three treatment cycles with a fixed injected activity of
4.4 GBq during each session. This seems surprising since
most trials using 90Y-DOTA-TOC base the dose on body
surface area or use a kidney absorbed dose adapted scheme
with dosimetric calculations during the first therapy cycle
[3–7]. It is also known that the kidney volume plays a
crucial role in the absorbed dose to the organ [8]. Therefore
an individually adapted dose scheme, based on body
surface area or individual dosimetry, should be chosen. If
individual dosimetry is performed in every patient and if
several treatment cycles are planned, dosimetry would be
most adequate when performed during the first treatment
cycle by adding 111In-DOTA-TOC. Pre-therapeutic dosim-
etry would then be unnecessary.
A careful reading of this article conveys the impression
that the main message is to exclude from treatment those
patients who would receive an absorbed dose to the kidney
higher than 27 Gy. This would deprive them of a palliative
treatment that also can potentially prolong life and improve
its quality [3, 9]. The fact that these cancer patients usually
have no other treatment options makes their exclusion from
treatment ethically unacceptable. Knowing the absorbed
dose to the kidney (mGy/MBq), it is obvious that these
patients can also be treated safely by a reduction in the
injected activity.
The authors state correctly that no clear data exist on the
relation between absorbed dose and irreversible renal tox-
icity in internal radiotherapy. For us this seems to be an-
other argument as to why 27 Gy can only be a guideline and
should not serve as a justification to exclude a patient from
treatment with an injected activity adjusted to give a kidney
dose of <27 Gy. For instance, 23 Gy was taken as the max-
imum allowed dose in another study [10].Moreover, the pre-
therapeutic kidney function of the patient has to be taken into
consideration. Of the patients we see, some have already had
treatments with potentially nephrotoxic agents such as cis-
platin or 131I-MIBG. An additional effect of toxicity is most
likely.
It has been shown that the distribution of radiolabelled
somatostatin analogues in the kidney is inhomogeneous
[11]. The kidney damage observed after internal radio-
therapy is located in glomeruli showing thrombotic micro-
angiopathy [12]. These facts indicate that kidney dosimetry
is much more complex than the way in which it is handled
by the MIRDOSE concept.
To conclude, the dosimetric results of this work are im-
portant and we are convinced that internal radiotherapy has
to be improved by means of dosimetry. But patients should
not be excluded from a beneficial treatment by adherence to
strict settings which are not proven and can be overcome. If
individual dosimetry is performed, we suggest that this
should be done peri-therapeutically during the first treatment
cycle with 111In-/90Y-DOTA-TOC. This is the most practical
method and also the most convenient method for patients.
The circumstances really represent the therapeutic situation.
The “commercial success” of Zevalin in countries where pre-
therapeutic dosimetry is demanded might give us a hint as to
where additional examinations may lead.
An authors’ reply to this letter is available at
http://dx.doi.org/10.1007/s00259-004-1727-2.
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European Journal of Nuclear Medicine and Molecular Imaging Vol. 32, No. 4, April 2005
References
1. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS,
et al. Affinity profiles for human somatostatin receptor subtypes
SST1-SST5 of somatostatin radiotracers selected for scintigraphic
and radiotherapeutic use. Eur J Nucl Med 2000;27(3):273–82.
2. Froidevaux S, Heppeler A, Eberle AN, Meier AM, Hausler M,
Beglinger C, et al. Preclinical comparison in AR4-2J tumor-
bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis
and internal radiotherapy. Endocrinology 2000;141(9):3304–12.
3.Waldherr C, Pless M, Maecke H, Schumacher T, Crazzolara A,
Nitzsche E, et al. Tumor response and clincical benefit in neuro-
endocrine tumors after 7.4 GBq 90Y-DOTATOC. J Nucl Med
2002;43:610–6.
4. Paganelli G, Bodei L, Handkiewicz Junak D, Rocca P, Papi S,
Lopera Sierra M, et al. 90Y-DOTA-D-Phe1-Try3-octreotide in ther-
apy of neuroendocrinemalignancies. Biopolymers 2002;66:393–8.
5. Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P,
et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl
Med 1999;26:1439–47.
6.Waldherr C, PlessM,MaeckeHR,HaldemannA,Mueller-Brand J.
The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-
DOTATOC) in the treatment of neuroendocrine tumours: a clinical
phase II study. Ann Oncol 2001;12(7):941–5.
7. Kwekkeboom D, Bakker W, Kam BLR, Teunissen J, Kooij P,
HerderW, et al. Treatment of patientswith gastro-entero-pancreatic
(GEP) tumours with the novel radiolabelled somatostatin analogue
[177Lu-DOTA0, Tyr3]octreotate. Eur J Nucl Med Mol Imaging
2003;30:417–22.
8. Konijnenberg MW. Is the renal dosimetry for [90Y-DOTA0,Tyr3]
octreotide accurate enough to predict thresholds for individual
patients? Cancer Biother Radiopharm 2003;18(4): 619–25.
9. Teunissen J, Kwekkeboom D, Krenning E. Quality of life in
patients with gastro-entero- pancreatic tumors treated with
[177Lu- DOTA0,Tyr3]octreotate. J Clin Oncol 2004;22:2724–9.
10. Jamar F, Barone R, Mathieu I, Walrand S, Labar D, Carlier P, et
al. 86Y-DOTA0-D-Phe1-Tyr3-octreotide (SMT 487)—a phase 1
clinical study: pharmacokinetics, biodistribution and renal pro-
tective effect of different regimens of amino acid co-infusion.
Eur J Nucl Med Mol Imaging 2003;30:510–8.
11. De Jong M, Valkema R, Van Gameren A, Van Boven H, Bex A,
Van De Weyer EP, et al. Inhomogeneous localization of radio-
activity in the human kidney after injection of [111In-DTPA]
octreotide. J Nucl Med 2004;45(7):1168–71.
12. Moll S, Nickeleit V, Mueller-Brand J, Brunner FP, Maecke HR,
Mihatsch MJ. A new cause of renal thrombotic microangiopathy:
yttrium-90-DOTATOC internal radiotherapy. Am J Kidney Dis
2001;37(4):847–51.
F. Forrer (*), J. Mueller-Brand.
Institute of Nuclear Medicine, University Hospital Basel,
Petersgraben 4, 4031 Basel, Switzerland
e-mail: fforrer@uhbs.ch
H. Maecke
Division of Radiological Chemistry, University Hospital Basel,
Basel, Switzerland
512
European Journal of Nuclear Medicine and Molecular Imaging Vol. 32, No. 4, April 2005
